ORF7 deficient varicella virus, vaccine comprising the virus and use thereof
US-10752885-B2 · Aug 25, 2020 · US
ORF7 deficient varicella virus, vaccine comprising the virus and use thereof
US11220673B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11220673-B2 |
| Application number | US-202016847360-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 13, 2020 |
| Priority date | Jul 28, 2009 |
| Publication date | Jan 11, 2022 |
| Grant date | Jan 11, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided are an ORF7 deficient varicella virus, an vaccine comprising the virus and use thereof, as well as a method for the production the virus.
First claim
Opening claim text (preview).
What is claimed is: 1. A vaccine against varicella and/or herpes zoster, comprising a varicella virus, and an excipient or carrier acceptable in vaccines, wherein the ORF7 of said varicella virus is entirely or partially deleted so that the resulting virus is unable to infect human skin or sensory ganglion, wherein the varicella virus is the varicella virus deposited in China General Microbiological Culture Collection Center, Institute of Microbiology Chinese Academy of Sciences, NO.1 West Beichen Road, Chaoyang District, Beijing 100101, China on Jul. 28, 2009 with deposit number CGMCC No.3207. 2. The vaccine according to claim 1 , wherein said ORF7 is entirely or partially replaced by antibiotic resistance genes. 3. The vaccine according to claim 2 , wherein said antibiotic resistance genes are selected from penicillin, streptomycin and kanamycin resistance genes. 4. A method of inducing an immune response against varicella and/or herpes zoster, comprising administering a prophylactic effective amount of the vaccine according to claim 1 . 5. An immunogenic composition comprising a prophylactic effective amount of the vaccine according to claim 1 .
Assignees
Inventors
Classifications
- A61K39/25Primary
Varicella-zoster virus · CPC title
avirulent or attenuated · CPC title
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title
for herpes viruses · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11220673B2 cover?
- Provided are an ORF7 deficient varicella virus, an vaccine comprising the virus and use thereof, as well as a method for the production the virus.
- Who is the assignee on this patent?
- Beijing Wantai Biological Pharmacy Entpr Co Ltd, Univ Rutgers, Univ Xiamen
- What technology area does this patent fall under?
- Primary CPC classification A61K39/25. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).